×

Biotech and Pharmaceuticals Life Sciences

  • *potential deal could come next week- Bloomberg. Dec 16- Shares in Swiss biopharmaceuticals company Actelion surged more than 8 percent to a record high after Bloomberg reported that talks with French suitor Sanofi were nearing an agreement that could be worth about $275 per share. The potential deal, which could come as soon as next week, would value Actelion at...

  • Capsugal purchase will create value: Lonza CEO

    Lonza CEO, Richard Ridinger, talks about the company’s strategic plans going into 2017, while commenting on Donald Trump’s influence on the sector.

  • Capsugel deal isn’t a short-term move: Lonza CEO

    Lonza CEO, Richard Ridinger, explains why the acquisition of Capsugel is “the perfect fit” for the pharmaceutical manufacturer.

  • Dec 14- Spain's Grifols SA, which develops plasma protein therapies, said it would buy U.S. medical device maker Hologic Inc's interest in their blood screening joint venture for $1.85 billion in cash. Grifols, which owns the customer-facing activities of the venture, said the acquired assets comprise a plant in San Diego, California as well as development...

  • In vitro fertilisation (IVF) being performed by a fertility doctor (right).

    A common chemotherapy drug has been found to help produce more eggs in a woman's ovaries, indicating a possible solution for low fertility.

  • Dec 3- An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday. The trial results were presented at a meeting of the American Society of Hematology in San Diego.

  • Dec 2- A promising but risky new group of customized cancer drugs will be in focus this weekend at the annual meeting of the American Society of Hematology, where clinical trial results will help clarify their potential for doctors and investors. "Juno has dug themselves into such a deep hole," said Brad Loncar, manager of the Loncar Cancer Immunotherapy ETF.

  • Dec 2- A promising but risky new group of customized cancer drugs will be in focus this weekend at the annual meeting of the American Society of Hematology, where clinical trial results will help clarify their potential for doctors and investors. "Juno has dug themselves into such a deep hole," said Brad Loncar, manager of the Loncar Cancer Immunotherapy ETF.

  • But when a drug already taken by thousands of people for intestinal conditions appeared to control the monkey version of HIV, it got the attention of the director of the National Institutes of Allergy and Infectious Diseases. Fauci hopped on a plane to Cambridge, Mass., to personally tell Japan's Takeda Pharmaceutical Co's U.S. representatives that their drug...

  • *Says company had 240 mln euros in cash end-Sept. PARIS, Nov 25- France's Innate Pharma believes that its cash position and portfolio are sufficiently robust for the cancer drug company to remain independent for the time being and will seek co-development deals modeled on an agreement struck with AstraZeneca in April. In August Pfizer announced the $14 billion...

  • LONDON, Nov 24- British privately owned biotech company Kymab has secured $100 million of funding from investors, including $36.5 million from China's Shenzhen Hepalink Pharmaceutical, to help to fund its pipeline of experimental antibody drugs. Kymab said on Thursday that ORI Healthcare Fund is also a new investor in the Cambridge- based business, which is...

  • *Head and neck cancer studies resume patient recruitment. LONDON, Nov 22- U.S. officials have given a green light for two clinical trials testing AstraZeneca's immunotherapy drug durvalumab in head and neck cancer to resume recruiting patients, lifting a hold imposed following cases of bleeding. Shares in AstraZeneca gained around 1 percent on Tuesday as the...

  • LONDON, Nov 22- U.S. officials have given a green light for two clinical trials testing AstraZeneca's cancer immunotherapy drug durvalumab in head and neck cancer to resume recruiting patients, lifting a hold imposed following cases of bleeding. The British drugmaker said on Tuesday that one of the late-stage Phase III trials had already re-opened for new...

  • BRIEF-GSK FILES REGULATORY SUBMISSION OF CANDIDATE VACCINE@. *GSK files regulatory submission of candidate vaccine for prevention of shingles in Canada. *Says regulatory submission for candidate shingles vaccine is based on a comprehensive phase III clinical trial program.

  • The companies are racing rivals including Eli Lilly, Alder Biopharmaceuticals, Allergan and Teva Pharmaceuticals to have a new, more effective migraine treatment approved by U.S. and European regulators. Jefferies analyst Jeffrey Holford, in a note on Thursday, forecast $1.5 billion in peak sales for the drug, with estimates for Novartis reaping about $440...

  • *Says will meet with FDA "as soon as possible". Dynavax Chief Executive Eddie Gray said on Monday the company would meet with the FDA "as soon as possible" to discuss concerns raised by the agency in a "complete response letter." The company said the FDA, in its letter, sought information about certain "adverse events" during clinical trials, among other clarifications.

  • *Says to meet with FDA "as soon as possible". The drug developer said on Monday it received a "complete response letter" from the FDA, seeking information about certain "adverse events" during clinical trials, among other clarifications. Dynavax Chief Executive Eddie Gray said the company would meet with the FDA "as soon as possible" to discuss the letter.

  • The drug developer said it received a "complete response letter" from the FDA, seeking information about certain "adverse events" during clinical trials, among other clarifications. Dynavax said there was no request from the FDA for additional clinical trials and there were no apparent concerns about rare serious events. Dynavax Chief Executive Eddie Gray...

  • Nov 14- Dynavax Technologies Corp said on Monday the U.S. Food and Drug Administration had rejected the marketing application for its hepatitis B vaccine Heplisav-B, sending the company's shares tumbling 44 percent in premarket trading. The drug developer said it received a "complete response letter" from the FDA, seeking information about certain "adverse...

  • SAN FRANCISCO, Nov 9- U.S. companies reacted on Wednesday with caution to businessman Donald Trump's victory in the U.S. presidential election and pointed to uncertainty over his lack of clear policy proposals. Following campaign promises by Trump to renegotiate global trade agreements and make U.S. companies move factories back to the United States, over...